Kerry A. Rogers

5.0k total citations
124 papers, 1.4k citations indexed

About

Kerry A. Rogers is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Kerry A. Rogers has authored 124 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Genetics, 52 papers in Pathology and Forensic Medicine and 39 papers in Immunology. Recurrent topics in Kerry A. Rogers's work include Chronic Lymphocytic Leukemia Research (119 papers), Lymphoma Diagnosis and Treatment (52 papers) and Immunodeficiency and Autoimmune Disorders (31 papers). Kerry A. Rogers is often cited by papers focused on Chronic Lymphocytic Leukemia Research (119 papers), Lymphoma Diagnosis and Treatment (52 papers) and Immunodeficiency and Autoimmune Disorders (31 papers). Kerry A. Rogers collaborates with scholars based in United States, Canada and Poland. Kerry A. Rogers's co-authors include Jennifer A. Woyach, John C. Byrd, Farrukh T. Awan, Seema A. Bhat, Ying Huang, Kami J. Maddocks, Gerard Lozanski, Jeffrey A. Jones, Amy S. Ruppert and Michael R. Grever and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Kerry A. Rogers

110 papers receiving 1.4k citations

Peers

Kerry A. Rogers
Seema A. Bhat United States
Paula Cramer Germany
Karim Maloum France
Lukáš Smolej Czechia
Celeste Bello United States
Richard Delarue France
Christina Balser Germany
Claire Dearden United Kingdom
Christian H. Geisler Denmark
Norma Peter Germany
Seema A. Bhat United States
Kerry A. Rogers
Citations per year, relative to Kerry A. Rogers Kerry A. Rogers (= 1×) peers Seema A. Bhat

Countries citing papers authored by Kerry A. Rogers

Since Specialization
Citations

This map shows the geographic impact of Kerry A. Rogers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerry A. Rogers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerry A. Rogers more than expected).

Fields of papers citing papers by Kerry A. Rogers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerry A. Rogers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerry A. Rogers. The network helps show where Kerry A. Rogers may publish in the future.

Co-authorship network of co-authors of Kerry A. Rogers

This figure shows the co-authorship network connecting the top 25 collaborators of Kerry A. Rogers. A scholar is included among the top collaborators of Kerry A. Rogers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerry A. Rogers. Kerry A. Rogers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rogers, Kerry A., Benyam Muluneh, Zaina P. Qureshi, et al.. (2025). A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases. Journal of Comparative Effectiveness Research. 14(6). e240210–e240210.
2.
Zhao, Qiuhong, Andrew Stiff, Seema A. Bhat, et al.. (2024). Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia. SHILAP Revista de lepidopterología. 5(5). 1005–1009.
3.
Ghosh, Nilanjan, Ruibin Wang, Zaina P. Qureshi, et al.. (2024). Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation. PubMed. 1(3). 100022–100022. 2 indexed citations
4.
Ruz, Patrick, Adam S. Kittai, Kerry A. Rogers, et al.. (2024). Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation. Leukemia. 38(10). 2141–2149. 5 indexed citations
5.
Omer, Zulfa, Jennifer A. Woyach, Seema A. Bhat, et al.. (2024). Clinical Characteristics and Outcome in a Cohort of CLL Patients with BTK T474 Gatekeeper Mutation. Blood. 144(Supplement 1). 1875–1875.
6.
Lu, Xiaoxiao, Bruno Émond, Zaina P. Qureshi, et al.. (2023). Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma. Current Medical Research and Opinion. 39(9). 1227–1235. 1 indexed citations
7.
Kittai, Adam S., Seema A. Bhat, Michael R. Grever, et al.. (2023). Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization. Blood Advances. 7(23). 7239–7242. 4 indexed citations
8.
Huang, Ying, Mirela Anghelina, Seema A. Bhat, et al.. (2023). Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2. SHILAP Revista de lepidopterología. 4(4). 1200–1202. 1 indexed citations
9.
Ghia, Paolo, Talha Munir, Jan A. Burger, et al.. (2023). P645: IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS. HemaSphere. 7(S3). e78258de–e78258de. 1 indexed citations
10.
Stephens, Deborah M., Ying Huang, Amy S. Ruppert, et al.. (2022). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clinical Cancer Research. 28(15). 3242–3247. 20 indexed citations
11.
12.
Bhat, Seema A., Marilly Palettas, Tracy Wiczer, et al.. (2022). Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood. 140(20). 2142–2145. 46 indexed citations
13.
Kittai, Adam S., Cecelia Miller, Ying Huang, et al.. (2021). The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood. 138(23). 2372–2382. 31 indexed citations
14.
Wiczer, Tracy, Marilly Palettas, Seema A. Bhat, et al.. (2021). Evaluation of the Incidence and Risk Factors Associated with Bleeding Events in Patients Receiving Acalabrutinib Therapy. Blood. 138(Supplement 1). 3729–3729. 4 indexed citations
15.
Woyach, Jennifer A., James S. Blachly, Kerry A. Rogers, et al.. (2020). Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. Cancer Discovery. 10(3). 394–405. 57 indexed citations
16.
Thangavadivel, Shanmugapriya, Qiuhong Zhao, Narendranath Epperla, et al.. (2020). Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. Clinical Cancer Research. 26(23). 6187–6195. 3 indexed citations
17.
Woyach, Jennifer A., James S. Blachly, Kerry A. Rogers, et al.. (2020). Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 136(Supplement 1). 16–18. 12 indexed citations
18.
Addison, Daniel, Janice M. Bonsu, Avirup Guha, et al.. (2019). REPORTING OF CARDIOVASCULAR EVENTS IN CLINICAL TRIALS SUPPORTING FDA-APPROVAL OF CONTEMPORARY CANCER DRUGS. Journal of the American College of Cardiology. 73(9). 1879–1879. 1 indexed citations
19.
Rogers, Kerry A., Luay Mousa, Qiuhong Zhao, et al.. (2017). Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. Blood. 130(Suppl_1). 830–830. 23 indexed citations
20.
Awan, Farrukh T., Shanmugapriya Thangavadivel, David M. Weiss, et al.. (2017). A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL. Blood. 130. 1748–1748. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seema A. Bhat Breakdown of academic impact, for papers by Paula Cramer Breakdown of academic impact, for papers by Karim Maloum Breakdown of academic impact, for papers by Lukáš Smolej Breakdown of academic impact, for papers by Celeste Bello Breakdown of academic impact, for papers by Richard Delarue Breakdown of academic impact, for papers by Christina Balser Breakdown of academic impact, for papers by Claire Dearden Breakdown of academic impact, for papers by Christian H. Geisler Breakdown of academic impact, for papers by Norma Peter
Rankless by CCL
2026